About Molecular Insight Pharmaceuticals
Molecular Insight Pharmaceuticals is a company based in Cambridge (United States) founded in 1997 was acquired by Progenics in January 2013. Molecular Insight Pharmaceuticals operates in a competitive market with competitors including ImaginAb, MDxHealth, AC Immune, GenomeDx Biosciences and APRINOIA, among others.
- Headquarter Cambridge, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Molecular Insight Pharmaceuticals Inc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Molecular Insight Pharmaceuticals
Investors in Molecular Insight Pharmaceuticals
Molecular Insight Pharmaceuticals has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include HHS and Progenics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Imaging compounds & targeted radiotherapies to detect and treat prostate cancer.
|
Locked | Locked | Locked |
Investor details for Molecular Insight Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Molecular Insight Pharmaceuticals
Investment portfolio details for Molecular Insight Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Molecular Insight Pharmaceuticals
Detailed financials for Molecular Insight Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Molecular Insight Pharmaceuticals Comparisons
Peer comparison for Molecular Insight Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Molecular Insight Pharmaceuticals
Molecular Insight Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ImaginAb, MDxHealth, AC Immune, GenomeDx Biosciences and APRINOIA, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
ImaginAb is focused on developing advanced immuno-oncology imaging technologies.
|
|
| Locked | Locked | Locked |
Epigenetic tests for personalized cancer assessment and treatment.
|
|
| Locked | Locked | Locked |
Antibodies, small molecules, and vaccines are developed for neurodegenerative diseases.
|
|
| Locked | Locked | Locked |
Genomic tests for urologic cancers are developed and commercialized.
|
|
| Locked | Locked | Locked |
Diagnostics and therapeutics for neurodegenerative disorders are developed.
|
|
| Locked | Locked | Locked |
Small molecule drugs and imaging agent for GI disorders
|
Detailed competitors of Molecular Insight Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Molecular Insight Pharmaceuticals
Complete news archive for Molecular Insight Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Molecular Insight Pharmaceuticals
Molecular Insight Pharmaceuticals was founded in 1997 and raised its 1st funding round 10 years after it was founded.
Molecular Insight Pharmaceuticals is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Molecular Insight Pharmaceuticals develops therapeutic radiopharmaceuticals and molecular imaging agents for use in oncology and cardiology. The company targets the development of a small-molecule chemistry platform to improve detection of primary and metastatic prostate cancer and to provide a systemic radiotherapy for relapsed and metastatic prostate cancer. Its products include technetium Tc 99m trofolastat, a clinical-stage molecular imaging agent for patients with metastatic prostate cancer; and 131I-MIP-1095, a prostate cancer therapy for systemic delivery of radiotherapy. As of January 18, 2013, Molecular Insight Pharmaceuticals operates as a subsidiary of Progenics Pharmaceuticals.